TT&A advised Quadria Capital in its acquisition of minority shareholding in Aragen Life Sciences Limited through a combination of primary and secondary investment for USD 100 million.

This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling Aragen to meet the growing demand for outsourcing services from innovators in the US and Europe. With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen and this partnership solidifies Aragen’s reputation for delivering high-quality “concept to clinic” and “concept to commercial” services to its global customer base comprising all sectors of health – Human, Animal and Plant.

TT&A Team: Gautam Saha – Joint Managing Partner; Amrita Patnaik – Partner; Ambika Sahai & Garvita Mehrotra – Managing Associates and Aditi Somani- Senior Associate.